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Abstract Teriparatide (rhPTH[1–34]) affects calcium
metabolism in a pattern consistent with the known actions
of endogenous parathyroid hormone (PTH). This report
describes the pharmacokinetics and resulting serum cal-
cium response to teriparatide in postmenopausal women
with osteoporosis. Pharmacokinetic samples for this anal-
ysis were obtained from 360 women who participated in
the Fracture Prevention Trial. Postmenopausal women with
osteoporosis received daily subcutaneous injections of
either teriparatide 20 lg (4.86 lmol) or placebo, median
21 months’ treatment. Serum teriparatide and calcium
concentrations were measured throughout the study. An
indirect-response model was developed to describe the
pharmacokinetic–pharmacodynamic relationship between
teriparatide concentrations and serum calcium response.
The pharmacokinetics of teriparatide were characterized by
rapid absorption (maximum concentration achieved within
30 min) and rapid elimination (half-life of 1 h), resulting in
a total duration of exposure to the peptide of approximately
4 h. Teriparatide transiently increased serum calcium, with
the maximum effect observed at approximately 4.25 h
(median increase 0.4 mg/dl [0.1 mmol/l]). Calcium con-
centrations returned to predose levels by 16–24 h after
each dose. Persistent hypercalcemia was not observed; one
teriparatide 20 lg-treated patient had a predose serum
calcium value above the normal range but \11.0 mg/dl
(2.75 mmol/l). Following once-daily subcutaneous admin-
istration, teriparatide produces a modest but transient
increase in serum calcium, consistent with the known
effects of endogenous PTH on mineral metabolism. The
excursion in serum calcium is brief, due to the short length
of time that teriparatide concentrations are elevated.
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The extracellular calcium concentration is of utmost
importance for maintenance of both intracellular and
extracellular processes playing a critical role in the regu-
lation of a variety of physiological functions. In response to
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DOI 10.1007/s00223-010-9424-6slight decrements in extracellular calcium levels, there is a
rapid (within seconds) increase in the rate of parathyroid
hormone (PTH) release into the systemic circulation [1, 2].
The most immediate effect of PTH is on the renal tubule,
where it stimulates conservation of calcium. This effect is
almost instantaneous and is the primary way PTH regulates
serum calcium minute by minute. If elevated for 1–2 h,
PTH stimulates translocation of calcium from an extra-
cellular compartment located between bone lining cells and
the bone surface into the circulation. Finally, if elevated for
several hours, PTH promotes intestinal absorption of cal-
cium by stimulating the conversion of 25-OH vitamin D to
the highly active 1,25-dihydroxyvitamin D [3]. PTH reg-
ulation by calcium, coupled with the rapid secretion and
rapid clearance (half-life\2 min) of the endogenous
hormone, assures that PTH can adjust to sudden changes in
plasma calcium ﬂux [4].
Teriparatide, recombinant human parathyroid hormone
(rhPTH[1–34]), is a skeletal anabolic agent that, when
injected subcutaneously once daily, increases bone mass
and reduces the risk of osteoporotic fracture [5–8]. Calcium
metabolism is affected in a pattern consistent with the
known actions of endogenous PTH. Given the role of PTH
in the regulation of extracellular calcium over both short-
and long-term periods, it is important to understand the
time course of the calcemic response to exogenously
administered teriparatide as well. The purpose of this
article is to describe the pharmacokinetics (PK) and
resulting serum calcium pharmacodynamic (PD) response
following subcutaneous injection of 20 lg (4.86 lmol) of
teriparatide in postmenopausal women with osteoporosis
participating in the Fracture Prevention Trial [6].
Materials and Methods
Study Design and Participants
Full details on the Fracture Prevention Trial have been
published elsewhere [6]. Postmenopausal women with
osteoporosis and prevalent fractures were randomized to
receive once-daily subcutaneous injections of teriparatide
20 lg( n = 541), teriparatide 40 lg( n = 552), or placebo
(n = 544) plus daily calcium (1,000 mg) and vitamin D
(400–1,200 IU) supplements. This report includes results
from the marketed 20-lg/day dose of teriparatide. Study
exclusion criteria included the following: diagnosis with
any disease known to affect bone or calcium metabolism,
urolithiasis within 2 years, serum creatinine level[2m g / d l ,
alcohol or drug abuse, and medication use known to alter
bone metabolism within the previous 2–24 months
depending on the drug. Patients who were treated with oral
bisphosphonates within 3 months of randomization or for
more than 60 days in the 24 months prior to randomization
or who were treated with intravenous bisphosphonate
within 24 months prior to randomization were excluded.
All study sites obtained institutional review board
approval. Written informed consent was given by each par-
ticipantpriortoherinclusioninthestudy.Studymethodsand
procedures were conducted in accordance with the ethical
standards of the 1964 Declaration of Helsinki.
Teriparatide and Calcium Measurements
Serum teriparatide concentrations were measured in a
subset of 360 patients at months 1, 3, 6, 12, and 18. One
blood sample was collected per patient at each study visit
within prespeciﬁed sampling windows of 0–30 min,
30 min–1 h, 1–2 h, 2–3 h, and 3–4 h postdose. The exact
postdose collection times were documented. The blood
sampling scheme was based on a sparse sampling strategy
such that a complete PK proﬁle was not obtained from each
patient but, rather, a few samples were drawn from many
patients and the data combined to characterize the PK
proﬁle for the population [9]. The serum was separated
from whole blood by centrifugation and stored at -70C
until assayed. Teriparatide was measured by a validated
two-site immunoradiometric assay (Phoenix International,
Montreal, Canada). Two different antibodies to the 1–34
region of PTH were supplied by Immutopics (San Cle-
mente, CA). One antibody was immobilized on a plastic
bead and used to capture teriparatide. The second antibody
was labeled with
125I and used to detect the bound
teriparatide.
The speciﬁcity of the assay was determined by using
PTH(1–34) and smaller fragments. The assay could detect
(1–31) but not (1–27) on the C terminus; it could also
detect (2–34) and (3–34) but not (4–34) on the N terminus.
The percent cross-reactivity of PTH(1–84), relative to the
PTH(1–34) standards, was 67% on a molar basis. However,
results from phase 1 and phase 3 studies demonstrated that
endogenous PTH secretion was dramatically suppressed
following teriparatide injection (data on ﬁle); thus, inter-
ference by endogenous PTH(1–84) in the quantiﬁcation of
PTH(1–34) was negligible. Serial blood samples collected
from a phase 1 study demonstrated that the decline in
PTH(1–84) concentrations was immediate, reaching a nadir
approximately 2 h postdose and remaining suppressed for
at least 6 h in most subjects. In the phase 3 study that is the
focus of this report, PTH(1–84) was measured at screening
and 12 months after initiation of teriparatide therapy.
During screening visits, prior to teriparatide treatment,
mean PTH(1–84) was 35 pg/ml; there were no samples
below the limit of quantiﬁcation for the PTH(1–84) assay,
i.e., \16.6 pg/ml. Following 12 months of teriparatide
treatment, 91% of the samples were below quantiﬁable
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trates the suppression of endogenous PTH secretion during
teriparatide therapy, suggesting minimal interference in the
detection of PTH(1–34).
The PTH(1–34) assay was validated to accurately and
reproduciblyquantifyexogenouslyadministeredPTH(1–34);
accuracy and precision were both ±20%. A standard curve
of 9.8–20,000 pg/ml was used with the quantiﬁcation range
of 50–2,000 pg/ml determined in the assay validation
experiments.
Blood samples for serum calcium were collected in all
patients at baseline (i.e., prerandomization) and 4–6 h after
injection at 1, 3, 6, 12, 18, and 24 months of treatment.
Additionally, routine clinical chemistry laboratory testing,
which included serum calcium, was performed at baseline
and at 1, 6, 12, and 24 months of treatment. The clinical
chemistry labs were collected at random times, and the
exact postdose collection time was documented. If the
calcium concentration was [10.6 mg/dl (2.647 mmol/l),
the test was normally repeated within a couple of weeks. If
the retest value was also elevated, the calcium supplement
dose was reduced or discontinued or the dose of the
injectable study material was reduced by half and the
serum calcium laboratory test repeated. If still elevated, the
patient was discontinued from the trial. Adverse events
were collected throughout the trial.
All clinical chemistry labs from an individual patient
were performed at one of three laboratories that used
identical, cross-calibrated methods of measurement. Serum
albumin was normal in the study population, and adjusting
serum calcium concentrations for albumin appeared only to
increase the variability of the measure without having a
signiﬁcant effect on the mean values; therefore, the unad-
justed total serum calcium is presented.
PK Model
A population PK model was ﬁrst developed to characterize
the concentration–time proﬁle following subcutaneous
injection of teriparatide [9, 10]. Both one-compartment and
two-compartment open linear models were considered for
the PK model. Absorption was assumed to follow a ﬁrst-
order process, and elimination was assumed to occur from
the central compartment in the two-compartment model.
These models were parameterized in terms of absorption
rate constant (Ka), apparent clearance (CL/F), central
compartment volume (Vc/F), intercompartmental clearance
(Q/F), and peripheral compartment volume (Vp/F).
PK–PD Model
A PK–PD model was also developed to characterize the
serum calcium response to daily teriparatide injection as a
function of time and teriparatide concentration. The PK–PD
analysis data set contained 3,085 calcium and 1,282 teri-
paratide concentrations obtained from 360 patients whose
age and weight ranged from 49 to 85 years (10th–90th
percentile range 60–77 years) and 39.5 to 120 kg (10th–
90th percentile range 51–80 kg) atstudyentry, respectively.
Baseline serum calcium values ranged from 8.28 to
10.6 mg/dl, mean value of 9.2 with a variability of 0.38 mg/
dl (±standard deviation [SD]). An indirect-response model
was developed using the following equation:
dCalcium
dt
¼ Kin   1 þ
Emax   CTPTD
EC50 þ CTPTD

  Kout   CCalcium
where Kin represents the zero-order production rate for
change in serum calcium over time; Kout is the ﬁrst-order
dissipation rate for calcium response; CCalcium and CTPTD
represent the calcium and teriparatide concentrations,
respectively; Emax is the maximum calcemic response; and
EC50 is the teriparatide concentration required to produce
50% of the maximum calcium effect.
Data Analysis Procedure
A sequential PK–PD analysis was performed, with the ﬁnal
parameter values from the population PK model being ﬁxed
during the PK–PD analysis. The PK and PK–PD models
were developed using nonlinear mixed-effects modeling
techniques in NONMEM (version VI) with PREDPP [11].
First-order conditional estimation with interaction (NON-
MEM User’s Guide, Part VII) was used for the PK model,
while ﬁrst-order estimation was used for the PK–PD model.
Additive and proportional interpatient variability models
were tested. Three residual error models—(1) additive, (2)
proportional, and (3) combined additive and proportional—
were also evaluated.
Model development strategies were consistent between
the PK and full PK–PD analyses. First, basic structural
models were built, with interpatient variability included on
all parameters where it was estimable. In addition, covari-
ance between parameters was tested using the OMEGA
BLOCK option in NONMEM. Second, factors potentially
inﬂuencing the PK and PD of teriparatide, including age,
body weight, injection site, creatinine clearance, smoking,
and alcohol history, were examined graphically and then
tested through estimation of covariate models.
A stepwise forward and backward approach was applied
such that each covariate was added or deleted one at a time.
When possible, physiologic relevance was considered in
covariate selection. However, the log-likelihood ratio test
was the primary criterion used to determine the appropri-
ateness of a selected covariate. A decrease in the objective
functionvalueofC6.635(P\0.01,degreeoffreedom = 1)
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thatthefullmodelwasthesuperiormodel.Ifthedifferencein
theobjectivefunctionvaluewas\6.635,thenitwasassumed
that there was no signiﬁcant difference between the two
models and the simpler reduced model (i.e., without covari-
ate) was retained.
Potentially signiﬁcant covariates were then added to the
base model in combination so that a full model containing
all possible covariates was established. Highly correlated
patient factors (e.g., age and years postmenopausal) were
evaluated separately and the most statistically signiﬁcant
covariate was retained. The process was then reversed,
with potential covariates being removed individually from
the full model. Finally, covariates retained in the ﬁnal
model were those which resulted in a signiﬁcant increase in
objective function (C10.828 points for 1 degree of free-
dom, P\0.001), when removed from the full model. The
ﬁt of the resulting model was evaluated using diagnostic
plots of predicted versus observed values, as well as a
visual predictive check [12].
Predose serum calcium was also analyzed by analysis of
covariance (ANCOVA), with baseline as a covariate using
SAS v.8.2 for MVS (SAS Institute, Cary, NC). The num-
bers of patients with calcium values[10.6 or[11.0 mg/dl
were compared between treatment groups using Fisher’s
exact test.
Results
The treatment groups were well balanced for baseline
characteristics and disease severity [6]. Previous osteopo-
rosis drug use was reported by 14.9 and 15.5% of patients
in the placebo and teriparatide 20 lg groups, respectively.
The mean (±SD) duration of teriparatide treatment during
the study was 18 ± 5 months in the placebo and
18 ± 6 months in the teriparatide 20 lg groups.
Teriparatide PK
The teriparatide concentration–time proﬁle is characterized
by rapid absorption and elimination with an obvious
monoexponential decline in concentrations. The peptide
reached a maximum concentration about 30 min after
subcutaneous injection and then declined with a half-life of
1 h. This half-life reﬂects the time required for absorption
from the injection site as the true elimination half-life
following intravenous administration was 5 min [13].
In most subjects, teriparatide concentrations were
\50 pg/ml by 3 h after injection of a 20-lg dose. By
extrapolating the teriparatide concentration–time proﬁle to
inﬁnite time, we estimated the duration of exposure above
the upper limit of normal for endogenous PTH (65 pg/ml)
and above basal concentrations (28 pg/ml). On a molar
basis, the teriparatide concentrations brieﬂy exceeded the
upper limit of normal for about 3 h and remained above
basal concentrations for about 4 h.
A one-compartment absorption rate-limited PK model
with ﬁrst-order elimination and interpatient variability on
CL/F, V/F, and Ka served as the base model for further
covariate search and model reﬁnement; a two-compartment
model did not signiﬁcantly improve the ﬁt of the data. Of
all the covariates tested, only body weight and injection
site were found to have small but statistically signiﬁcant
inﬂuences on the rate of teriparatide absorption. No asso-
ciation was found between age, smoking, alcohol history,
or renal function and teriparatide PK. Injections into the
thigh were estimated to have a 21% slower rate of
absorption than abdominal wall injections, resulting in an
18% reduction in maximum teriparatide concentrations
(Cmax) and 1.5 min prolongation in the time to reach the
peak concentration (Tmax). Similarly, the rate of absorption
was slower in heavier patients, resulting in a 26% reduction
in Cmax and a 2.3 min prolongation in Tmax, when com-
paring the 10th and 90th percentiles of weight values in the
analysis data set. The slower rates of absorption did not
affect the overall systemic exposure to teriparatide. Fur-
thermore, population PD analyses demonstrated no statis-
tically signiﬁcant differences in lumbar spine BMD or
biochemical marker responses based on body weight or
injection site (data not shown). Therefore, the magnitude of
the effects of body weight and injection site on the rate of
teriparatide absorption, and the resultant peak serum con-
centrations, is not considered to be clinically meaningful.
The Ka of 0.63 h
-1 supports the assertion of absorption
rate-limited PK since the half-life based upon this rate con-
stant (i.e., ln 2/0.63 h
-1 = 1.1 h) is consistent with the
observed half-life of teriparatide following subcutaneous
injection. Interpatient variability, expressed as percent
coefﬁcient of variation (CV), was 30%. Teriparatide CL/F
(approximately62 l/h,46%CV)exceededtherateofnormal
liver plasma ﬂow, consistent with the known hepatic and
extrahepatic mechanisms of PTH metabolism and clearance
[3, 14–16]. The V/F following subcutaneous administration
was approximately 7.8 l (107% CV). The proportional and
additive residual error terms were estimated to be 40% and
16 pg/ml (SD), respectively. The PK parameters were esti-
mated with good precision, with standard errors of estima-
tion (%SEE) B10% for the primary PK parameters (Ka, CL/
F,andV/F)and%SEE B 25%forallotherﬁxedandrandom
effect parameters in the model.
Calcium PD
The uncorrected serum calcium concentration vs. time pro-
ﬁles are shown for teriparatide 20 lg-treated patients
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range for uncorrected serum calcium is 8.2–10.6 mg/dl. A
placebo-responsemodelwasnotdevelopedbecausecalcium
levels were not increased after oral calcium administration.
The baseline serum calcium level was estimated from
the PK–PD model to be 9.2 mg/dl (2.3 mmol/l, 3.0% CV).
The PD parameter estimates that characterized the rela-
tionship between teriparatide concentration and calcemic
response were Kin = 1.1 mg/(dl   hour), Kout = 0.12 h
-1,
Emax = 19.5% (62% CV), and EC50 = 54 pg/ml. The
residual error was estimated to be 4.0%. The %SEE for the
PD parameters was B35%. None of the covariates tested,
including age, body weight, smoking, alcohol history, and
injection site, had a statistically signiﬁcant effect on
calcemic response to teriparatide. The visual predictive
check for the ﬁnal PK–PD model is shown in Figure 2. The
relationship between serum teriparatide concentrations and
the resulting calcemic response based on the PK–PD model
is illustrated in Figure 3.
Following daily injections of teriparatide 20 lg, the
serum calcium concentration increased transiently, begin-
ning approximately 2 h after dosing and reaching a
maximum concentration at 4.25 h (median increase,
0.4 mg/dl [0.1 mmol/l]). Fifty patients (9.4%) in the teri-
paratide 20 lg group had serum calcium levels above the
upper limit of normal 4–6 h after dosing compared with six
cases (1.1%) in the placebo group (P\0.001). The serum
calcium concentration began to decline approximately 6 h
after dosing and returned to predose levels by 16–24 h after
each dose. Because the calcium concentrations returned to
predose values prior to administration of the next dose,
there was neither a sustained elevation in the calcemic
response nor accumulation over time.
Fig. 1 Serum calcium concentrations vs. time since last teriparatide
20 lg( a) or placebo (b) dose. The upper (10.6 mg/dl, 2.64 mmol/l)
and lower (8.2 mg/dl) limits of normal for serum calcium are shown
by the horizontal lines
Fig. 2 Visual predictive check of ﬁnal PK–PD model. Solid lines
represent the 90% conﬁdence intervals for the 5th, median, and 95th
percentiles of model simulated results. Dotted lines represent the 5th,
median, and 95th percentiles calculated from the observed data. Data
were binned in ranges of 0–2, 2–4, 4–6, 6–24, and 24–30 h for the
calculation of percentiles. The observed data are overlaid for
reference
Fig. 3 Model predicted teriparatide concentration–time proﬁle and
the resulting serum calcium response following teriparatide 20 lg
injection. Upper (10.6 mg/dl, 2.64 mmol/l) and lower (8.2 mg/dl)
limits of normal for serum calcium are shown by the horizontal lines.
IQR interquartile range
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Approximately 25% ofthe serum calcium samples collected
at months 1, 6, and 12 and 8% of the samples at months 3,
18, and 24 were obtained in the 16- to 24-h postdose interval
andformedthebasisforthepredoseserumcalciumanalysis.
Mean (±standard error [SE]) predose serum calcium val-
ues at baseline, 1, 3, 6, 12, 18, and 24 months were 9.20 ±
0.02, 9.19 ± 0.03, 9.12 ± 0.08, 9.29 ± 0.03, 9.40 ± 0.03,
9.30 ± 0.08, and 9.26 ± 0.05 mg/dl, respectively, for the
teriparatide 20 lg-treated patients and 9.22 ± 0.02, 9.09 ±
0.03, 8.93 ± 0.09, 9.09 ± 0.03, 9.27 ± 0.03, 9.31 ± 0.08,
and 9.18 ± 0.05 mg/dl, respectively, for the placebo-trea-
ted patients. Baseline serum calcium did not differ between
treatment groups. Predose serum calcium was signiﬁcantly
(P\0.05) higher than baseline at 6 and 12 months (?0.09
and ?0.2 mg/dl, respectively) for teriparatide-treated
patients. In contrast, for placebo-treated patients, the
predose serum calcium values were signiﬁcantly (P\0.05)
lower than baseline at 1 and 6 months (-0.13 and
-0.13 mg/dl, respectively) and signiﬁcantly (P\0.05)
higher than baseline at 12 months (?0.05 mg/dl). There
were no statistically signiﬁcant treatment differences in the
incidence of elevated serum calcium above the normal
range. One teriparatide 20 lg-treated patient (0.4%, 1/223)
had a predose serum calcium value [10.6 mg/dl and no
teriparatide 20 lg-treated patient had a predose serum cal-
cium[11.0 mg/dl. In the placebo group, one patient (0.4%,
1/237) had a predose serum calcium value[10.6 mg/dl and
onepatient(0.4%,1/237)hadapredoseserumcalciumvalue
[11.0 mg/dl.
To determine whether the transient increases in postdose
serum calcium values were associated with any clinical
adverse effects commonly associated with hypercalcemia,
adverse events in patients in the teriparatide group who
had elevated ([10.6 mg/dl or 2.647 mmol/l) postdose
serum calcium are summarized in comparison with the
overall cohort of patients receiving teriparatide 20 lg/day
(Table 1). Except for a case of acute pancreatitis (n = 1),
there were no speciﬁc outstanding safety ﬁndings observed
inthosepatientswhohadhypercalcemiaduringthecourseof
thetrial.Theanalysiswaslimitedbecauseofthelownumber
of cases.
Discussion
Our results demonstrate that the duration of calcemic
response after the subcutaneous injection of teriparatide
20 lg is brief. One reason for this is the rapid rates of
absorption and elimination of teriparatide. After subcuta-
neous injection, maximum teriparatide concentrations are
achieved within 30 min, followed by a rapid decline from
the systemic circulation with a half-life of 1 h. Teriparatide
transiently increases serum calcium, with the maximal
effect observed at approximately 4.25 h (median increase,
0.4 mg/dl or 0.1 mM) followed by a decline to predose
levels before the next teriparatide dose is administered 24 h
later.
The results of studies in rats have also shown that the
therapeutic interval for PTH(1–34) exposure is brief but
that prolonged exposure results in severe hypercalcemia.
Using a total daily dose of 80 lg/kg body weight of
hPTH(1–34), Dobnig and Turner [17] demonstrated that a
single subcutaneous injection or continuous infusion for 1
or 2 h/day had no effect on serum calcium. In contrast,
continuous infusion of hPTH(1–34) for 6 h/day resulted in
hypercalcemia. Frolik et al. [18] conﬁrmed that sustained
elevated serum calcium concentrations occurred following
subcutaneous injections of teriparatide every hour for six
injections but not following once-daily subcutaneous
injection of teriparatide or six injections within 1 h.
The PK–PD proﬁle of teriparatide 20 lg has practical
clinical implications because the PK and calcium PD
results show notable differences compared to those of the
full human recombinant PTH (rhPTH[1–84]), which is also
available for the treatment of osteoporosis in some coun-
tries at a daily dose of 100 lg.
The PK and PD of single-dose rhPTH(1–84) subcuta-
neous injection (dose range 0.02–5.0 lg/kg) were reported
by Schwietert et al. [19]. The serum concentration–time
proﬁle of rhPTH(1–84) exhibited a double-peak proﬁle,
with the ﬁrst peak appearing approximately 5–10 min after
Table 1 Adverse events commonly associated with hypercalcemia
summarized in patients treated with teriparatide 20 lg/day who had
elevated ([10.6 mg/dl) 4–6 h postdose serum calcium in comparison
with the overall cohort of patients in the teriparatide group
Overall cohort
a
(n = 541)
Patients
a with serum
Ca[10.6 (n = 50)
Neurological
Headache 44 (8.1%) 4 (8.0%)
Depression 21 (3.9%) 3 (6.0%)
Gastrointestinal
Abdominal pain 48 (8.9%) 6 (12.0%)
Pancreatitis 1 (0.2%) 1 (2.0%)
Nausea 51 (9.4%) 6 (12.0%)
Anorexia 8 (1.5%) 1 (2.0%)
Constipation 32 (5.9%) 6 (12.0%)
Vomiting 19 (3.5%) 3 (6.0%)
Peptic ulcer/gastritis 8 (1.5%) 2 (4.0%)
Cardiovascular
Arrhythmias 9 (1.7%) 1 (2.0%)
Hypertension 41 (7.6%) 4 (8.0%)
a n (%)
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subcutaneous injection of this hormone [19]. Interestingly,
at all rhPTH(1–84) doses administered, there was a ﬁxed
equilibrium between elevated PTH(1–84) and PTH(1–34),
a biologically active fragment of PTH(1–84) that was
further accompanied by a double-peak proﬁle in serum
total calcium concentrations [19]. The apparent terminal
half-life of rhPTH(1–84) was reported to be 1.5–2.5 h [19,
20]. In contrast, the time to peak concentration of teri-
paratide is 30 min following injection, with a half-life of
1h[ 13].
Based on the PK concentration–time proﬁle for each
drug, we calculated the duration of time that PTH concen-
trations were [65 pg/ml, the upper limit of normal for
endogenous PTH, and[28 pg/ml, the typical basal endog-
enous PTH concentration for postmenopausal women.
Using the published PK proﬁle [19] for rhPTH(1–84), we
calculated that the time above the upper limit exceeded 6 h
and the time above basal concentrations exceeded 9 h for
the marketed dose of 100 lg (1.66 lg/kg, assuming an
average body weight of 60 kg). In contrast, teriparatide
concentrations exceeded the upper limit of normal and
remained above the basal concentrations for approximately
3 and 4 h, respectively. Such differences compared to the
PK–PD relationship of teriparatide could translate into
the formation of a longer ‘‘drug exposure time’’ for rhPTH-
(1–84) compared with teriparatide. Indeed, the resulting
calcemic response elicited by 100 lg rhPTH(1–84) led to a
peak serum calcium increase of 0.6 mg/dl (0.15 mmol/l)
between6and8 hpostdose[20].Theseapparentdifferences
in the duration of exposure may help to explain why
hypercalcemia and hypercalciuria are relatively rare events
following administration of teriparatide 20 lg[ 6, 21, 22],
although they have been more frequently reported in the
rhPTH(1–84) 100 lg pivotal trial [23]. Whether it is the
slower rate of absorption and elimination of rhPTH(1–84)
due to its larger size and/or the parallel generation of
PTH(1–34) and possibly other biologically active amino-
terminal PTH fragments whose biological half-lives are less
well characterized that leads to a larger calcemic response
than teriparatide has yet to be determined.
Another potential explanation for the differences in the
calcemic responses is that the dose of rhPTH(1–84) used in
the pivotal phase 3 trial (100 lg/day, 10.62 lmol/day) [23]
is approximately twofold greater on a molar basis than
teriparatide 20 lg. However, it has been reported that the
bioavailability of rhPTH(1–84) is 55% [24] compared with
the 95% bioavailability of teriparatide [25]. Thus, when
adjusting for molecular weight and bioavailability, the
relative doses administered in the rhPTH(1–84) pivotal
phase 3 trial [23] and the teriparatide Fracture Prevention
Trial [6] were 5.84 and 4.61 lmol, respectively, a differ-
ence that is unlikely to explain the disparity in the rates of
hypercalcemia or drug exposure time between the two
studies.
In conclusion, the pharmacologic effect of teriparatide
following once-daily subcutaneous administration pro-
duces a modest but transient increase in serum calcium,
consistent with the known effects of endogenous PTH on
mineral metabolism. The PK–PD indirect-response model
illustrates that the excursion in serum calcium is brief due
to the short length of time that teriparatide concentrations
are elevated.
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